

Disclosure Statement

A Joint Working Project between: The Innovation Agency, Academic Health Science Network for the North West Coast AND BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD

Name of Project:	Title: Embedding new ways of working to reduce Atrial Fibrillation (AF) related strokes in the North West Coast (Extension to Joint Working Agreement CVUK1800591-04)
Project Overview:	<p>The Innovation Agency, Academic Health Science Network for the North West Coast in partnership with Bristol-Myers Squibb Pharmaceuticals Limited (acting on behalf of the BMS/ Pfizer Alliance) have agreed to enter into a Joint Working Partnership for the benefit of patients who are at risk of, or who have been diagnosed with Atrial Fibrillation to; “Embed new ways of working to reduce Atrial Fibrillation (AF) related strokes” across three Clinical Commissioning Groups (CCGs) within the North West region of England.</p> <ul style="list-style-type: none"> • St. Helens CCG • Liverpool CCG • Morecambe Bay CCG <p>This project is an extension of the Joint Working Agreement between the BMS/ Pfizer Alliance and the Innovation Agency, AHSN for the North West Coast which concluded in June, 2019 (Job Code: CVUK180059104).</p> <p>The purpose of the extension is to enable the continued roll-out of the programme of work, focussing on the delivery of the three objectives</p>
Project Objectives:	<p><u>Objective 1 – Improving Care and Outcomes</u></p> <p>Support local healthcare teams across GP practices to improve the quality of care, management and outcomes for patients at risk of, or who have suffered an AF related stroke by delivering increased clinical education and quality improvement training. A minimum of 10% more patients in each practice will be managed in accordance with NICE guidanceⁱ.</p> <p><u>Objective 2– Patient Activation and Management</u></p> <p>Support greater understanding of what patients with AF require to be activated and engaged with their ongoing treatment. A series of interviews and focus groups will be held with approximately 20 patients. A set of “top tips” for AF engagement will be developed as a result of this work. This will form the basis of ongoing work with the Innovation Agency around medicines optimisation.</p> <p><u>Objective 3 – Increasing Detection and Diagnosis</u></p> <p>Deliver a 5% increase in detection of patients with AF through opportunistic screening; to include opportunistic screening in flu clinics in Autumn 2019.</p>
Patient Benefits:	<ul style="list-style-type: none"> • Patients will benefit from the rapid implementation of the national guidance and best practice across the three clinical commissioning groups;

	<ul style="list-style-type: none"> • Increased numbers of patients will be identified through case finding, and appropriately anti-coagulated, reducing their risk of stroke; • It is anticipated that the patient awareness of Atrial Fibrillation (AF) along with their understanding of why and how to take their medicines will improve; • Patients registered at GP practices across the three CCGs will have improved access to, and consistency of service provision for the treatment of Atrial Fibrillation, including increased access to opportunistic screening for AF.
Stakeholders:	<ul style="list-style-type: none"> • Bristol-Myers Squibb Pharmaceuticals Limited on behalf of the BMS/ Pfizer Alliance. • The Innovation Agency, Academic Health Science Network for the North West Coast
Timelines:	The project extension will commence in November 2019 for a period of 6 months.

ⁱ National Institute for Health and Care Excellence (NICE) Clinical Guidance (CG) 180: Atrial Fibrillation Management. Updated August 2014. Link: <https://www.nice.org.uk/guidance/cg180>.